Compare ELME & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELME | FATE |
|---|---|---|
| Founded | 1960 | 2007 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.5M | 125.6M |
| IPO Year | 1994 | 2013 |
| Metric | ELME | FATE |
|---|---|---|
| Price | $1.66 | $2.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $12.67 | $4.10 |
| AVG Volume (30 Days) | 631.0K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | ★ 707.44% | N/A |
| EPS Growth | N/A | ★ 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $206,360,000.00 | $6,646,000.00 |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.26 | $0.94 |
| 52 Week High | $17.68 | $3.23 |
| Indicator | ELME | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 52.88 |
| Support Level | $1.46 | $2.27 |
| Resistance Level | $1.67 | $2.55 |
| Average True Range (ATR) | 0.03 | 0.13 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 40.00 | 59.04 |
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. It derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Elme Communities' tenants are banking, consulting, law, and financial services firms. The company operates in a single reportable segment which includes the ownership, development, redevelopment and acquisition of apartment communities.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.